Which has better earnings & valuation, NVO or NVS?

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $327.80B 0.67 $15.51B $4.26 11.49 Novartis $54.53B 5.41 $13.98B $6.98 22.16

Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Novartis 24.87% 38.82% 15.16%

Does the media favor NVO or NVS?

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Novartis. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 9 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.89 beat Novartis' score of 0.66 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 18 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings and valuation, NVO or AZN?

Novo Nordisk A/S has higher revenue and earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $327.80B 0.67 $15.51B $4.26 11.49 Astrazeneca $58.74B 4.72 $10.23B $6.66 26.82

Does the media refer more to NVO or AZN?

In the previous week, Novo Nordisk A/S had 5 more articles in the media than Astrazeneca. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 24 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.89 beat Astrazeneca's score of 0.69 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 18 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 11 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $327.80B 0.67 $15.51B $4.26 11.49 GSK $43.07B 2.46 $7.54B $3.85 13.61

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% GSK 17.82% 44.28% 11.49%

Does the media refer more to NVO or GSK?

In the previous week, Novo Nordisk A/S had 23 more articles in the media than GSK. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 6 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.89 beat GSK's score of -0.01 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 18 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, NVO or SNY?

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $327.80B 0.67 $15.51B $4.26 11.49 Sanofi $49.35B 2.15 $8.84B $3.58 12.24

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Sanofi 16.95% 13.39% 7.58%

Does the media favor NVO or SNY?

In the previous week, Novo Nordisk A/S had 23 more articles in the media than Sanofi. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 6 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.89 beat Sanofi's score of 0.14 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 18 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ARGX or NVO?

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 13.35 $1.29B $22.46 40.60 Novo Nordisk A/S $327.80B 0.67 $15.51B $4.26 11.49

Is ARGX or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media refer more to ARGX or NVO?

In the previous week, Novo Nordisk A/S had 26 more articles in the media than argenex. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 3 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.48 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 18 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Novo Nordisk A/S (NVO) Competitors

$48.90 +0.01 (+0.02%)

As of 02:27 PM Eastern

Compare

NVO vs. NVS, AZN, GSK, SNY, and ARGX

Should you buy Novo Nordisk A/S stock or one of its competitors? MarketBeat compares Novo Nordisk A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novo Nordisk A/S include Novartis (NVS), Astrazeneca (AZN), GSK (GSK), Sanofi (SNY), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Novo Nordisk A/S compare to Novartis?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Novartis	24.87%	38.82%	15.16%

Novo Nordisk A/S currently has a consensus price target of $65.56, suggesting a potential upside of 33.93%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 8.71%. Given Novo Nordisk A/S's higher probable upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, Novo Nordisk A/S had 20 more articles in the media than Novartis. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 9 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.89 beat Novartis' score of 0.66 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	18 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.6%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has higher revenue and earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.67	$15.51B	$4.26	11.49
Novartis	$54.53B	5.41	$13.98B	$6.98	22.16

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Novo Nordisk A/S beats Novartis on 12 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Novo Nordisk A/S (NYSE:NVO) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Novo Nordisk A/S presently has a consensus target price of $65.56, indicating a potential upside of 33.93%. Astrazeneca has a consensus target price of $211.00, indicating a potential upside of 18.12%. Given Novo Nordisk A/S's higher possible upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Astrazeneca's net margin of 17.19%. Novo Nordisk A/S's return on equity of 63.31% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Astrazeneca	17.19%	30.86%	12.68%

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.6%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 5 more articles in the media than Astrazeneca. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 24 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.89 beat Astrazeneca's score of 0.69 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	18 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	11 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive

Novo Nordisk A/S has higher revenue and earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.67	$15.51B	$4.26	11.49
Astrazeneca	$58.74B	4.72	$10.23B	$6.66	26.82

Summary

Novo Nordisk A/S beats Astrazeneca on 12 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to GSK?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Novo Nordisk A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.67	$15.51B	$4.26	11.49
GSK	$43.07B	2.46	$7.54B	$3.85	13.61

Novo Nordisk A/S currently has a consensus target price of $65.56, suggesting a potential upside of 33.93%. GSK has a consensus target price of $53.00, suggesting a potential upside of 1.14%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

In the previous week, Novo Nordisk A/S had 23 more articles in the media than GSK. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 6 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.89 beat GSK's score of -0.01 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	18 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
GSK	17.82%	44.28%	11.49%

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.6%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novo Nordisk A/S beats GSK on 14 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Sanofi?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Sanofi	16.95%	13.39%	7.58%

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Novo Nordisk A/S presently has a consensus price target of $65.56, suggesting a potential upside of 33.93%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 12.96%. Given Novo Nordisk A/S's higher possible upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.67	$15.51B	$4.26	11.49
Sanofi	$49.35B	2.15	$8.84B	$3.58	12.24

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.6%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Novo Nordisk A/S had 23 more articles in the media than Sanofi. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 6 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.89 beat Sanofi's score of 0.14 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	18 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to argenex?

argenex (NASDAQ:ARGX) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

argenex has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to argenex's net margin of 31.31%. Novo Nordisk A/S's return on equity of 63.31% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novo Nordisk A/S has higher revenue and earnings than argenex. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	13.35	$1.29B	$22.46	40.60
Novo Nordisk A/S	$327.80B	0.67	$15.51B	$4.26	11.49

60.3% of argenex shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

argenex currently has a consensus target price of $1,037.61, suggesting a potential upside of 13.79%. Novo Nordisk A/S has a consensus target price of $65.56, suggesting a potential upside of 33.93%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Novo Nordisk A/S	1 Sell rating(s)	17 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Novo Nordisk A/S had 26 more articles in the media than argenex. MarketBeat recorded 29 mentions for Novo Nordisk A/S and 3 mentions for argenex. Novo Nordisk A/S's average media sentiment score of 0.89 beat argenex's score of 0.48 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	18 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Novo Nordisk A/S on 9 of the 17 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$218.58B	$333.25B	$6.89B	$23.47B
Dividend Yield	3.52%	2.67%	2.67%	4.01%
P/E Ratio	11.49	29.92	27.39	31.30
Price / Sales	0.67	5.08	497.13	84.34
Price / Cash	10.59	14.40	49.24	25.14
Price / Book	7.44	8.47	10.94	4.78
Net Income	$15.51B	$11.61B	$3.57B	$1.07B
7 Day Performance	-2.84%	-1.90%	0.17%	-0.40%
1 Month Performance	15.96%	7.86%	5.50%	1.57%
1 Year Performance	-29.87%	27.58%	31.03%	16.75%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.4104 of 5 stars	$48.95 +0.1%	$65.56 +33.9%	-29.8%	$218.58B	$327.80B	11.49	69,505	Trending News Analyst Forecast
NVS Novartis	2.8308 of 5 stars	$155.65 -0.9%	$141.20 -9.3%	+27.5%	$297.12B	$54.53B	22.31	75,267
AZN Astrazeneca	4.8131 of 5 stars	$190.52 -1.3%	$205.33 +7.8%	+35.3%	$295.59B	$58.74B	28.62	96,100	Trending News Gap Down
GSK GSK	3.2082 of 5 stars	$52.70 -1.2%	$53.00 +0.6%	+36.5%	$106.83B	$43.07B	13.71	66,841	Dividend Cut Analyst Upgrade
SNY Sanofi	4.3086 of 5 stars	$42.87 -0.3%	$49.50 +15.5%	-11.2%	$103.98B	$49.35B	11.98	74,846	News Coverage Analyst Forecast Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 7/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, GSK, SNY, and ARGX

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to GSK?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Summary

How does Novo Nordisk A/S compare to argenex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. NVS, AZN, GSK, SNY, and ARGX

How does Novo Nordisk A/S compare to Novartis?

Which has more volatility & risk, NVO or NVS?

Is NVO or NVS more profitable?

Do analysts recommend NVO or NVS?

Does the media favor NVO or NVS?

Is NVO or NVS a better dividend stock?

Which has better earnings & valuation, NVO or NVS?

Do institutionals & insiders have more ownership in NVO or NVS?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Do analysts prefer NVO or AZN?

Do institutionals and insiders hold more shares of NVO or AZN?

Which has more volatility and risk, NVO or AZN?

Is NVO or AZN more profitable?

Is NVO or AZN a better dividend stock?

Does the media refer more to NVO or AZN?

Which has higher earnings and valuation, NVO or AZN?

Summary

How does Novo Nordisk A/S compare to GSK?

Which has more volatility and risk, NVO or GSK?

Do institutionals and insiders hold more shares of NVO or GSK?

Which has stronger valuation & earnings, NVO or GSK?

Do analysts recommend NVO or GSK?

Does the media refer more to NVO or GSK?

Is NVO or GSK more profitable?

Is NVO or GSK a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Is NVO or SNY more profitable?

Do institutionals and insiders believe in NVO or SNY?

Which has more volatility and risk, NVO or SNY?

Do analysts rate NVO or SNY?

Which has higher valuation & earnings, NVO or SNY?

Is NVO or SNY a better dividend stock?

Does the media favor NVO or SNY?

Summary

How does Novo Nordisk A/S compare to argenex?

Which has more risk and volatility, ARGX or NVO?

Is ARGX or NVO more profitable?

Which has preferable earnings & valuation, ARGX or NVO?

Do insiders & institutionals have more ownership in ARGX or NVO?

Do analysts prefer ARGX or NVO?

Does the media refer more to ARGX or NVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools